Tom is responsible for national key account PAXgene opportunities as well as leading sales and logistics activities between BD and Qiagen. In addition Tom is a member of the BD Cell and Biomarker Team as an Associate Sales Manager. In this role, Tom is accountable for driving growth across the CBP Portfolio of Products as well as creating solutions for his customers across the Life Science Research Market.
Liquid Biopsy Showcase:
PreAnalytiX, a joint venture between BD and QIAGEN, and sells systems for sample collection, stabilization and purification of high-quality nucleic acids from human specimens. The Company serves healthcare institutions, academic researchers, clinical laboratories and the pharmaceutical industry.
Integrated Collection, Stabilization, And Purification Of Circulating Cell-free DNA
Apoptosis and lysis of white blood cells in unstabilized whole blood releases intracellular DNA into plasma, which dilutes naturally occurring ccfDNA. PAXgene Blood ccfDNA Tubes contain an additive that anticoagulates blood and stabilizes blood cells via a non-crosslinking stabilization solution. This helps prevent the release of intracellular DNA and maintains constant ccfDNA levels during sample transport and storage prior to processing. When used with PAXgene Blood ccfDNA Tubes, the proven magnetic particle technology of the QIAsymphony PAXgene Blood ccfDNA Kit provides a rapid, automated procedure to isolate ccfDNA of high quality and purity.
The PMWC 2020 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).